$-0.60
(Market cap
$5,551 Mln
Recently Viewed
Clear AllMarket cap
$5,551 Mln
Revenue (TTM)
$1,476 Mln
P/E Ratio
23.3
P/B Ratio
3
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
15.2
Debt to Equity
0
Book Value
$10.8
EPS
$1.4
Face value
--
Shares outstanding
166,252,718
CFO
$704.48 Mln
EBITDA
$-213.72 Mln
Net Profit
$-921.08 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Alkermes (ALKS)
| 19.0 | 20.2 | -0.9 | 22.7 | 6.8 | 11.0 | -1.7 |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Alkermes (ALKS)
| -2.7 | 14.2 | 12.3 | 16.6 | -2.2 | -30.9 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Alkermes (ALKS)
|
33.3 | 5,551.1 | 1,475.9 | 241.7 | 20.6 | 14.7 | 23.3 | 3.0 |
| 20.3 | 1,256.1 | 0.0 | -48.3 | -- | -21 | -- | 4.5 | |
| 10.8 | 578.7 | 9.7 | -244.1 | -1,810.6 | -63.6 | -- | 2.1 |
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The... company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Read more
Chairman & CEO
Mr. Richard F. Pops
Chairman & CEO
Mr. Richard F. Pops
Headquarters
Dublin
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Alkermes plc (ALKS) is $33.31 (NASDAQ) as of 24-Apr-2026 16:00 EDT. Alkermes plc (ALKS) has given a return of 6.84% in the last 3 years.
The P/E ratio of Alkermes plc (ALKS) is 23.29 times as on 24-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
19.54
|
2.60
|
|
2024
|
13.05
|
3.27
|
|
2023
|
13.27
|
3.92
|
|
2022
|
-25.22
|
3.82
|
|
2021
|
-72.65
|
3.15
|
The 52-week high and low of Alkermes plc (ALKS) are Rs 36.48 and Rs 25.17 as of 26-Apr-2026.
Alkermes plc (ALKS) has a market capitalisation of $ 5,551 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Alkermes plc (ALKS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.